Healthcare Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
Myanmar Pharmaceuticals and Healthcare Report Q2 2015

Myanmar Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 25 2015
New investment reforms lifting restrictions on the foreign funding of medicine production will make Myanmar an attractive market to international generic drugmakers. This is due to the opportunity of securing a first-mover advantage in this frontier market, as well as being a result of rising medicine consumption. Nonetheless, we highlight that there is significant political uncertainty in Myanmar with the upcoming 2015 elections which poses as a risk to investment.
 
$1,295.00
Romania Pharmaceuticals and Healthcare Report Q2 2015

Romania Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 25 2015
$1,295.00
Slovenia Pharmaceuticals and Healthcare Report Q2 2015

Slovenia Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 25 2015
Our updated forecasts for Slovenia's pharmaceutical and healthcare expenditure indicate a rebound this year from a decline trend that was seen over the past three years. Admittedly, this is true in local currency terms, while the value in USD is expected to take a significant hit, especially in pharmaceutical sales.
 

Headline Expenditure Projections 

$1,295.00
Canada Pharmaceuticals and Healthcare Report Q2 2015

Canada Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 25 2015
Supported by strong democratic institutions and a long history of stable political Leadership, Canada is home to the second largest pharmaceutical market in the Americas and one of the largest in world. We believe that drugmakers will continue to realise considerable rewards, as sales of patented pharmaceuticals settle into a trend of steady growth, which is only nominally affected by the particularly slow penetration of generics.
 
$1,295.00
France Pharmaceuticals and Healthcare Report Q2 2015

France Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 25 2015
France will remain among the largest pharmaceutical markets worldwide in the coming years, especially due to a large and aging population, as well as high per capita spending levels on medicines. However, several cost-containment measures will continue to exert downward pressure on market growth over a multi-year horizon. On the upside, current macroeconomic trends, including low oil and food prices, should be net positive for household consumption in France, posing upside risks to market forecasts in the medium- and long-term.
$1,295.00
Lebanon Pharmaceuticals and Healthcare Report Q2 2015

Lebanon Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 25 2015
Lebanon's healthcare system is under enormous strain as the number of Syrian refugees seeking treatment in the country has sharply risen. Continued political instability will negatively impact government policy regarding healthcare and will in turn put the pharmaceutical sector at risk. However, high per capita spending, an increasing burden of non-communicable diseases along with efforts by the Health Ministry to tackle high levels of corruption within the sector will help sustain market growth in the coming years.
 
$1,295.00
Jordan Pharmaceuticals and Healthcare Report Q2 2015

Jordan Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015

BMI View: Jordan's government is attempting to achieve universal healthcare coverage, which we believe
will become increasingly possible following the decision to no longer provide free medical treatment to
Syrian refugees in Jordan. The government will have more funds to invest in the development of the public
healthcare sector, which was previously overburdened with refugees, though regional instability will
continue to weigh on Jordan's attractiveness as a medical tourism destination.
Headline Expenditure Projections

$1,295.00
Mauritius Pharmaceuticals and Healthcare Report Q1 2015

Mauritius Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Feb 18 2015
With high per-capita pharmaceutical expenditure and a stong governmental interest in pharmaceutical development, combined with a rising demand for non-communicable and chronic disease therapies, Mauritius plays host as an attractive destination for future growth - although the destination still remains relatively untouched on a local level.
 

Headline Expenditure Projections

$1,295.00
Mozambique Pharmaceuticals and Healthcare Report Q2 2015

Mozambique Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
$1,295.00
New Zealand Pharmaceuticals and Healthcare Report Q2 2015

New Zealand Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
$1,295.00
Peru Pharmaceuticals and Healthcare Report Q2 2015

Peru Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
Longstanding trade agreements with the US and EU, along with efficient regulations for quality control will continue to make Peru an appealing destination for drugmakers. However, while the pharmaceutical and healthcare markets continue to grow, the national economy continues to struggle and its dependence on key exports will hamper overall growth in the short-term.
 

Headline Expenditure Projections 

$1,295.00
Poland Pharmaceuticals and Healthcare Report Q2 2015

Poland Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
The Polish pharmaceutical market is heavily dependent on public healthcare spending; any negative economic developments will have an impact on the market in the short term. Over the past five years, Poland's economic outperformance has been vital to maintaining positive growth for the private and public healthcare sectors.
 
$1,295.00
Argentina Pharmaceuticals and Healthcare Report Q2 2015

Argentina Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
Despite economic activity forecast to continue to decline over the medium-term, Argentina's gradual transition towards more pragmatic and market-friendly economic policies will likely benefit key economic sectors in the long-term, including the pharmaceutical industry. We sustain our view that undervalued local drugmakers could be acquisition targets for foreign firms willing to enhance their footprint in the region as the economy stabilizes.
 
$1,295.00
Singapore Pharmaceuticals and Healthcare Report Q2 2015

Singapore Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
Singapore will remain a highly attractive manufacturing base for international pharmaceutical companies due to minimal levels of operational risks and the government's support for the industry. The pharmaceutical industry has been a key pillar of the country's economy and we believe its importance will continue to grow as traditional drivers such as electronic manufacturing slow.
 

Headline Expenditure Projections 

$1,295.00
Bulgaria Pharmaceuticals and Healthcare Report Q2 2015

Bulgaria Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
In 2015, we expect the fallout from the banking and NHIF funding crises to impact pharmaceutical and healthcare spending, but given the passage of reforms to healthcare financing, we hold a more positive view for the long term development of the pharmaceutical & healthcare sector.
 

Headline Expenditure Projections 

$1,295.00
Tanzania Pharmaceuticals and Healthcare Report Q2 2015

Tanzania Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
Tanzania's pharmaceutical market will continue to see growth with the continuing expansion of the country's National Health Insurance Fund. We highlight opportunities in the Tanzanian healthcare market which have come about thanks to the government's plans to introduce compulsory health insurance for households and its commitment to expanding healthcare coverage in underserved areas.
 

Headline Expenditure Projections 

$1,295.00
Germany Pharmaceuticals and Healthcare Report Q2 2015

Germany Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
$1,295.00
Hong Kong Pharmaceuticals and Healthcare Report Q2 2015

Hong Kong Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
The Hong Kong government will continue to shift healthcare provision towards the private sector due to the growing financial strain and an overburdened public healthcare system. While this could create cost barriers to medicines, we highlight that the strong earning power of the majority of the population as well as a robust private healthcare system will continue to offer strong commercial opportunities for drugmakers.
 

Headline Expenditure Projections 

$1,295.00
Japan Pharmaceuticals and Healthcare Report Q2 2015

Japan Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 18 2015
Japan's healthcare system will come under increasing financial strain due to the ageing population and the high use of patented medicines. This provides an impetus for the government to use cost containment measures including policies to encourage the uptake of generic drug medicines, posing a downside risk for R&D-based pharmaceutical companies
 

Headline Expenditure Projections 

$1,295.00
Colombia Pharmaceuticals and Healthcare Report Q2 2015

Colombia Pharmaceuticals and Healthcare Report Q2 2015

Date Published: Feb 11 2015
President Juan Manuel Santos continues to push forward healthcare reform for medicine price controls and regulatory reformation. Though, such reforms still leave scepticism as Colombia's struggling economy and expanding counterfeit drug market continue to hinder progress for the Colombian government and pharmaceutical market.
 

Headline Expenditure Projections 

$1,295.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data